

WOAH Reference Laboratory Reports Activities 2022

Activities in 2022

This report has been submitted : 9 mars 2023 13:55

Laboratory Information

Name of disease (or topic) for which you are a designated WOAH Reference Laboratory:	Bovine viral diarrhoea virus
Address of laboratory:	Elizabeth Macarthur Agriculture Institute. Woodbridge Road
Tel.:	0246406331
E-mail address:	peter.kirkland@dpi.nsw.gov.au
Website:	
Name (including Title) of Head of Laboratory (Responsible Official):	Dr P.D. Kirkland Manager, Virology Laboratory
Name (including Title and Position) of WOAH Reference Expert:	Peter Kirkland, Senior Principal Research Scientist
Which of the following defines your laboratory? Check all that apply:	Governmental

TOR1: DIAGNOSTIC METHODS

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (Not for quality control, proficiency testing or staff training)

Yes

Diagnostic Test	Indicated in WOAH Manual (Yes/No)	Total number of test performed last year	
Indirect diagnostic tests		Nationally	Internationally
BVD VNT	Yes	7500	0
BVDV AGID	Yes	6700	0

BVDV Indirect ELISA (Ab)	Yes	650	0
Direct diagnostic tests		Nationally	Internationally
BVD Virus isolation	Yes	2900	1200
BVDV antigen ELISA	Yes	12200	0
qRT-PCR	Yes	1300	0

TOR2: REFERENCE MATERIAL

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by WOA?H?

No

3. Did your laboratory supply standard reference reagents (nonWOAH-approved) and/or other diagnostic reagents to WOA?H Members?

No

4. Did your laboratory produce vaccines?

Not applicable

5. Did your laboratory supply vaccines to WOA?H Members?

Not applicable

TOR3: NEW PROCEDURES

6. Did your laboratory develop new diagnostic methods for the designated pathogen or disease?

No

7. Did your laboratory validate diagnostic methods according to WOA?H Standards for the designated pathogen or disease?

No

8. Did your laboratory develop new vaccines for the designated pathogen or disease?

No

9. Did your laboratory validate vaccines according to WOA?H Standards for the designated pathogen or disease?

No

TOR4: DIAGNOSTIC TESTING FACILITIES

10. Did your laboratory carry out diagnostic testing for other WOA?H Members?

Yes

NAME OF WOA?H MEMBER COUNTRY SEEKING ASSISTANCE	DATE	WHICH DIAGNOSTIC TEST USED	NO. SAMPLES RECEIVED FOR PROVISION OF DIAGNOSTIC SUPPORT	NO. SAMPLES RECEIVED FOR PROVISION OF CONFIRMATORY DIAGNOSES
NEW ZEALAND	2022-08-01	BVDV VNT	2,000	0

11. Did your laboratory provide expert advice in technical consultancies on the request of an WOA?H Member?

No

TOR5: COLLABORATIVE SCIENTIFIC AND TECHNICAL STUDIES

12. Did your laboratory participate in international scientific studies in collaboration with WOA Members other than the own?

No

TOR6: EPIZOOLOGICAL DATA

14. Did your Laboratory collect epidemiological data relevant to international disease control?

Yes

IF THE ANSWER IS YES, PLEASE PROVIDE DETAILS OF THE DATA COLLECTED:

Genotyping of strains of BVDV

15. Did your laboratory disseminate epidemiological data that had been processed and analysed?

No

16. What method of dissemination of information is most often used by your laboratory? (Indicate in the appropriate box the number by category and list the details in the box)

a) Articles published in peer-reviewed journals:

0

b) International conferences:

0

c) National conferences:

0

d) Other (Provide website address or link to appropriate information):

TOR7: SCIENTIFIC AND TECHNICAL TRAINING

17. Did your laboratory provide scientific and technical training to laboratory personnel from other WOA Members?

No

TOR8: QUALITY ASSURANCE

18. Does your laboratory have a Quality Management System?

Yes

Quality management system adopted	Certificate scan (PDF, JPG, PNG format)	
ISO17025		NATA Vet Certificate 30.11.2021.pdf

19. Is your quality management system accredited?

Yes

Test for which your laboratory is accredited	Accreditation body
All BVDV assays	NATA

20. Does your laboratory maintain a "biorisk management system" for the pathogen and the disease concerned?

No

TOR9: SCIENTIFIC MEETINGS

21. Did your laboratory organise scientific meetings related to the pathogen in question on behalf of WOA?

No

22. Did your laboratory participate in scientific meetings related to the pathogen in question on behalf of WOA?

Yes

Title of event	Date (mm/yy)	Location	Role (speaker, presenting poster, short communications)	Title of the work presented
----------------	-----------------	----------	--	-----------------------------------

TOR10: NETWORK WITH WOA REFERENCE LABORATORIES

23. Did your laboratory exchange information with other WOA Reference Laboratories designated for the same pathogen or disease?

Yes

24. Are you a member of a network of WOA Reference Laboratories designated for the same pathogen?

No

25. Did you organise or participate in inter-laboratory proficiency tests with WOA Reference Laboratories designated for the same pathogen?

No

26. Did your laboratory collaborate with other WOA Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?

No

TOR11: OTHER INTERLABORATORY PROFICIENCY TESTING

27. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than WOA Reference Laboratories for the same pathogen?

Yes

Purpose for inter-laboratory test	Role of your reference laboratory	No. participating	Region(s) of participating WOA
-----------------------------------	-----------------------------------	-------------------	--------------------------------

comparisons ¹	(organizer/participant)	laboratories	Member Countries
National standardisation	Participant, provision of reference materials	6	Asia and Pacific

TOR12: EXPERT CONSULTANTS

28. Did your laboratory place expert consultants at the disposal of WOA?

No

29. Additional comments regarding your report:

Yes

Regarding vaccines, we did not develop new vaccines per se but undertook R & D for the development and evaluation of 3 new vaccines with commercial manufacturers